Antigen delivery to antigen-presenting cells (APCs) is a key issue in developing eŠective cancer vaccines. Controlling the tissue distribution of antigens, which are administered in a peptide/protein or DNA form, can increase antigenspeciˆc immune responses, including the induction of cytotoxic T lymphocytes. Heat-shock protein 70 (Hsp70), a member of a highly conserved family of molecular chaperones, forms complexes with a variety of tumor-related antigens via its polypeptide binding domain. Because Hsp70 is taken up by APCs through the recognition by Hsp receptors, such as CD91 and LOX-1, its application to antigen delivery systems has been examined both in experimental and clinical settings. A tissue distribution study revealed that Hsp70 is mainly taken up by the liver, especially by hepatocytes, after intravenous injection in mice. A signiˆcant amount of Hsp70 was also delivered to regional lymph nodes when it was injected subcutaneously, supporting the hypothesis that Hsp70 is a natural targeting system to APCs. Model antigens were complexed with or conjugated to Hsp70, by which greater antigen-speciˆc immune responses were achieved. Cytoplasmic delivery of Hsp70-antigen further increased the e‹cacy of the Hsp70-based vaccines. Theseˆndings indicate that eŠective cancer therapy can be achieved by developing Hsp70-based anticancer vaccines when their tissue and intracellular distribution is properly controlled.
. Roles of Hsp70 in Immune Response
Hsp70 is recognized by signaling receptors, such as CD40 and Toll-like receptor (TLR)-2 and TLR-4, on APCs, activates nuclear factor-kB (NF-kB), then upregulates the expression of costimulatory molecules and MHC class II and induces the secretion of cytokines/chemokines. In addition, Hsp70 is recognized by Hsp receptors, such as LOX-1 and CD91, and internalized. When antigen peptides are bound or conjugated to Hsp70, the internalized peptides can be processed and presented on MHC molecules. 
